Cargando…

Genetic and epigenetic modifications induced by chemotherapeutic drugs: human amniotic fluid stem cells as an in-vitro model

BACKGROUND: Bleomycin, etoposide and cisplatin (BEP) are three chemotherapeutic agents widely used individually or in combination with each other or other chemotherapeutic agents in the treatment of various cancers. These chemotherapeutic agents are cytotoxic; hence, along with killing cancerous cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Upadhyaya, Prabin, Di Serafino, Alessandra, Sorino, Luca, Ballerini, Patrizia, Marchisio, Marco, Pierdomenico, Laura, Stuppia, Liborio, Antonucci, Ivana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6816179/
https://www.ncbi.nlm.nih.gov/pubmed/31660974
http://dx.doi.org/10.1186/s12920-019-0595-3
_version_ 1783463332470063104
author Upadhyaya, Prabin
Di Serafino, Alessandra
Sorino, Luca
Ballerini, Patrizia
Marchisio, Marco
Pierdomenico, Laura
Stuppia, Liborio
Antonucci, Ivana
author_facet Upadhyaya, Prabin
Di Serafino, Alessandra
Sorino, Luca
Ballerini, Patrizia
Marchisio, Marco
Pierdomenico, Laura
Stuppia, Liborio
Antonucci, Ivana
author_sort Upadhyaya, Prabin
collection PubMed
description BACKGROUND: Bleomycin, etoposide and cisplatin (BEP) are three chemotherapeutic agents widely used individually or in combination with each other or other chemotherapeutic agents in the treatment of various cancers. These chemotherapeutic agents are cytotoxic; hence, along with killing cancerous cells, they also damage stem cell pools in the body, which causes various negative effects on patients. The epigenetic changes due to the individual action of BEP on stem cells are largely unknown. METHODS: Human amniotic fluid stem cells (hAFSCs) were treated with our in-vitro standardized dosages of BEP individually, for seven days. The cells were harvested after the treatment and extraction of DNA and RNA were performed. Real-time PCR and flow cytometry were conducted for cell markers analysis. The global DNA methylation was quantified using 5mC specific kit and promoter and CpG methylation % through bisulfite conversion and pyrosequencing. Micro- RNAs (miRNAs) were quantified with real-time qPCR. RESULTS: The cytotoxic nature of BEP was observed even at low dosages throughout the experiment. We also investigated the change in the expression of various pluripotent and germline markers and found a significant change in the properties of the cells after the treatments. The methylation of DNA at global, promoter and individual CpG levels largely get fluctuated due to the BEP treatment. Several tested miRNAs showed differential expression. No positive correlation between mRNA and protein expression was observed for some markers. CONCLUSION: Cytotoxic chemotherapeutic agents such as BEP were found to alter stem cell properties of hAFSCs. Different methylation profiles change dynamically, which may explain such changes in cellular properties. Data also suggests that the fate of hAFSCs after treatment may depend upon the interplay between the miRNAs. Finally, our results demonstrate that hAFSCs might prove to be a suitable in-vitro model of stem cells to predict genetic and epigenetic modification due to the action of various drugs.
format Online
Article
Text
id pubmed-6816179
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-68161792019-10-31 Genetic and epigenetic modifications induced by chemotherapeutic drugs: human amniotic fluid stem cells as an in-vitro model Upadhyaya, Prabin Di Serafino, Alessandra Sorino, Luca Ballerini, Patrizia Marchisio, Marco Pierdomenico, Laura Stuppia, Liborio Antonucci, Ivana BMC Med Genomics Research Article BACKGROUND: Bleomycin, etoposide and cisplatin (BEP) are three chemotherapeutic agents widely used individually or in combination with each other or other chemotherapeutic agents in the treatment of various cancers. These chemotherapeutic agents are cytotoxic; hence, along with killing cancerous cells, they also damage stem cell pools in the body, which causes various negative effects on patients. The epigenetic changes due to the individual action of BEP on stem cells are largely unknown. METHODS: Human amniotic fluid stem cells (hAFSCs) were treated with our in-vitro standardized dosages of BEP individually, for seven days. The cells were harvested after the treatment and extraction of DNA and RNA were performed. Real-time PCR and flow cytometry were conducted for cell markers analysis. The global DNA methylation was quantified using 5mC specific kit and promoter and CpG methylation % through bisulfite conversion and pyrosequencing. Micro- RNAs (miRNAs) were quantified with real-time qPCR. RESULTS: The cytotoxic nature of BEP was observed even at low dosages throughout the experiment. We also investigated the change in the expression of various pluripotent and germline markers and found a significant change in the properties of the cells after the treatments. The methylation of DNA at global, promoter and individual CpG levels largely get fluctuated due to the BEP treatment. Several tested miRNAs showed differential expression. No positive correlation between mRNA and protein expression was observed for some markers. CONCLUSION: Cytotoxic chemotherapeutic agents such as BEP were found to alter stem cell properties of hAFSCs. Different methylation profiles change dynamically, which may explain such changes in cellular properties. Data also suggests that the fate of hAFSCs after treatment may depend upon the interplay between the miRNAs. Finally, our results demonstrate that hAFSCs might prove to be a suitable in-vitro model of stem cells to predict genetic and epigenetic modification due to the action of various drugs. BioMed Central 2019-10-28 /pmc/articles/PMC6816179/ /pubmed/31660974 http://dx.doi.org/10.1186/s12920-019-0595-3 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Upadhyaya, Prabin
Di Serafino, Alessandra
Sorino, Luca
Ballerini, Patrizia
Marchisio, Marco
Pierdomenico, Laura
Stuppia, Liborio
Antonucci, Ivana
Genetic and epigenetic modifications induced by chemotherapeutic drugs: human amniotic fluid stem cells as an in-vitro model
title Genetic and epigenetic modifications induced by chemotherapeutic drugs: human amniotic fluid stem cells as an in-vitro model
title_full Genetic and epigenetic modifications induced by chemotherapeutic drugs: human amniotic fluid stem cells as an in-vitro model
title_fullStr Genetic and epigenetic modifications induced by chemotherapeutic drugs: human amniotic fluid stem cells as an in-vitro model
title_full_unstemmed Genetic and epigenetic modifications induced by chemotherapeutic drugs: human amniotic fluid stem cells as an in-vitro model
title_short Genetic and epigenetic modifications induced by chemotherapeutic drugs: human amniotic fluid stem cells as an in-vitro model
title_sort genetic and epigenetic modifications induced by chemotherapeutic drugs: human amniotic fluid stem cells as an in-vitro model
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6816179/
https://www.ncbi.nlm.nih.gov/pubmed/31660974
http://dx.doi.org/10.1186/s12920-019-0595-3
work_keys_str_mv AT upadhyayaprabin geneticandepigeneticmodificationsinducedbychemotherapeuticdrugshumanamnioticfluidstemcellsasaninvitromodel
AT diserafinoalessandra geneticandepigeneticmodificationsinducedbychemotherapeuticdrugshumanamnioticfluidstemcellsasaninvitromodel
AT sorinoluca geneticandepigeneticmodificationsinducedbychemotherapeuticdrugshumanamnioticfluidstemcellsasaninvitromodel
AT ballerinipatrizia geneticandepigeneticmodificationsinducedbychemotherapeuticdrugshumanamnioticfluidstemcellsasaninvitromodel
AT marchisiomarco geneticandepigeneticmodificationsinducedbychemotherapeuticdrugshumanamnioticfluidstemcellsasaninvitromodel
AT pierdomenicolaura geneticandepigeneticmodificationsinducedbychemotherapeuticdrugshumanamnioticfluidstemcellsasaninvitromodel
AT stuppialiborio geneticandepigeneticmodificationsinducedbychemotherapeuticdrugshumanamnioticfluidstemcellsasaninvitromodel
AT antonucciivana geneticandepigeneticmodificationsinducedbychemotherapeuticdrugshumanamnioticfluidstemcellsasaninvitromodel